(S (NP (JJ Survival) (NN analysis)) (VP (VBZ has) (VP (VBN been) (VP (VBN developed) (CC and) (VBN applied) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS areas))) (PP (VBG including) (NP (NN manufacturing) (, ,) (NN finance) (, ,) (NNS economics) (CC and) (NN healthcare)))))))) (. .))
(S (PP (IN In) (NP (NN healthcare) (NN domain))) (, ,) (S (ADVP (RB usually)) (NP (JJ clinical) (NNS data)) (VP (VBP are) (ADJP (JJ high-dimensional) (, ,) (JJ sparse) (CC and) (JJ complex)))) (CC and) (S (ADVP (RB sometimes)) (NP (EX there)) (VP (VBZ exists) (NP (NP (JJ few) (NN amount)) (PP (IN of) (NP (NN time-to-event) (PRN (-LRB- -LRB-) (VBN labeled) (-RRB- -RRB-)) (NNS instances)))))) (. .))
(S (ADVP (RB Therefore)) (S (VP (VBG building) (NP (DT an) (NN accurate) (NN survival) (NN model)) (PP (IN from) (NP (JJ electronic) (NN health) (NNS records))))) (VP (VBZ is) (ADJP (VBG challenging))) (. .))
(S (PP (IN With) (NP (DT this) (NN motivation))) (, ,) (NP (PRP we)) (VP (VP (VBP address) (NP (DT this) (NN issue))) (CC and) (VP (VB provide) (NP (NP (DT a) (JJ new) (NN survival) (NN analysis) (NN framework)) (VP (VBG using) (NP (NP (JJ deep) (NN learning)) (CC and) (NP (JJ active) (NN learning))) (PP (IN with) (NP (DT a) (JJ novel) (NN sampling) (NN strategy))))))) (. .))
(S (ADVP (RB First)) (, ,) (NP (PRP$ our) (NN approach)) (VP (VP (VBZ provides) (NP (NP (JJR better) (NN representation)) (PP (IN with) (NP (JJR lower) (NNS dimensions)))) (PP (IN from) (NP (JJ clinical) (NNS features))) (S (VP (VBG using) (NP (ADJP (VBN labeled) (PRN (-LRB- -LRB-) (NN time-to-event) (-RRB- -RRB-)) (CC and) (ADJP (JJ unlabeled)) (PRN (-LRB- -LRB-) (VBN censored) (-RRB- -RRB-))) (NNS instances))))) (CC and) (RB then) (VP (ADVP (RB actively)) (VBZ trains) (NP (DT the) (NN survival) (NN model)) (PP (IN by) (S (VP (VBG labeling) (NP (DT the) (VBN censored) (NNS data)) (S (VP (VBG using) (NP (DT an) (NN oracle))))))))) (. .))
(S (PP (IN As) (NP (DT a) (JJ clinical) (JJ assistive) (NN tool))) (, ,) (NP (PRP we)) (VP (VBP introduce) (NP (NP (DT a) (JJ simple) (JJ effective) (NN treatment) (NN recommendation) (NN approach)) (VP (VBN based) (PP (IN on) (NP (PRP$ our) (JJ survival) (NN model)))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ experimental) (NN study))) (, ,) (NP (PRP we)) (VP (VBP apply) (NP (PRP$ our) (NN approach)) (PP (IN on) (NP (NP (NNP SEER-Medicare) (NNS data)) (VP (VBN related) (PP (TO to) (NP (NP (VB prostate) (NN cancer)) (PP (IN among) (NP (NP (NNPS African-Americans)) (CC and) (NP (JJ white) (NNS patients)))))))))) (. .))
(S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (PRP$ our) (NN approach)) (VP (VBZ outperforms) (ADVP (ADVP (RB significantly)) (PP (IN than) (NP (NN baseline) (NNS models)))))))) (. .))
